Depressive disorder, major Trials in Rostov-on-Don, Russia
Conditions / Depressive disorder, major / Rostov-on-Don, Russia
Clinical trials for Depressive disorder, major investigate a range of treatment strategies and patient populations.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02473289 | An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder | COMPLETED | PHASE2 |
| NCT02709655 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) | COMPLETED | PHASE3 |
| NCT03559192 | A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression | COMPLETED | PHASE2 |
| NCT01255787 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder | COMPLETED | PHASE2/PHASE3 |
| NCT00795821 | A Study in Adult Patients With Major Depressive Disorder | COMPLETED | PHASE2/PHASE3 |
| NCT02709746 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) | COMPLETED | PHASE3 |
| NCT03227224 | A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy | COMPLETED | PHASE2 |
| NCT01360866 | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | COMPLETED | PHASE3 |
| NCT01360632 | Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) | COMPLETED | PHASE3 |
| NCT02871297 | Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age | TERMINATED | PHASE3 |